Cellenkos, Inc.
Clinical trials sponsored by Cellenkos, Inc., explained in plain language.
-
Cord blood cells aim to tame deadly transplant complication
Disease control Not yet recruitingThis early-phase trial tests a new treatment called CK0802 for people with severe graft-versus-host disease (GVHD) that does not respond to steroids. GVHD is a serious complication after a bone marrow or stem cell transplant, where donor immune cells attack the patient's body. CK…
Phase: PHASE1, PHASE2 • Sponsor: Cellenkos, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Cord blood cells aim to break transfusion dependence in aplastic anemia
Disease control Not yet recruitingThis study tests a new treatment called CK0801 for adults with aplastic anemia who still need blood transfusions after standard therapy. CK0801 uses immune cells from donated cord blood to help the body make its own blood cells again. The trial will check if the treatment is safe…
Phase: PHASE2 • Sponsor: Cellenkos, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC